openPR Logo
Press release

Global Malignant Melanoma Drug Market & Clinical Pipeline Insight Report

05-07-2018 08:25 AM CET | Health & Medicine

Press release from: Kuick Resarch

Global Malignant Melanoma Drug Market & Clinical Pipeline

“Global Malignant Melanoma Drug Market & Clinical Pipeline Insight” Report Highlight:

* Global Malignant Melanoma Market Analysis
* Malignant Melanoma Drug Mechanism of Action
* Global Malignant Melanoma Clinical Pipeline By Company & Phase
* Global Malignant Melanoma Clinical Pipeline: 201 Drugs
* Majority Malignant Melanoma Drugs in Preclinical Phase: 63 Drugs
* Global Malignant Melanoma Marketed Drugs Clinical Insight
* Marketed Malignant Melanoma Drugs: 25 Drugs

Download Report Sample Weblink:

https://www.kuickresearch.com/report-Global-Malignant-Melanoma-Drug-Market-&-Clinical-Pipeline-Insight.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

1. Introduction to Malignant Melanoma



2. Malignant Melanoma Drug Mechanism of Action



3. Global Malignant Melanoma Market Analysis

3.1 Current Market Scenario

3.2 Global Malignant Melanoma Pipeline Overview



4. Global Malignant Melanoma Drug Market Dynamics

4.1 Favorable Market Parameters

4.2 Commercialization Challenges



5. Global Malignant Melanoma Drug Market Future Prospects



6. Global Malignant Melanoma Clinical Pipeline By Company & Phase

6.1 Unknown

6.2 Research

6.3 Preclinical

6.4 Clinical

6.5 Phase-I

6.6 Phase-I/II

6.7 Phase-II

6.8 Phase-II/III

6.9 Phase-III

6.10 Registered



7. Global Malignant Melanoma Marketed Drugs Clinical Insight

7.1 Talimogene Laherparepvec (IMLYGIC)

7.2 Nivolumab (Opdivo)

7.3 Temozolomide (Temodal & Temodar)

7.4 Peginterferon alfa-2b (Cylatron, Intron A Peg, PEG-Intron A, Pegatron, Pegintron, Pegtron & ViraferonPeg )

7.5 Pembrolizumab (Keytruda )

7.6 Vemurafenib

7.7 Ipilimumab (Yervoy)

7.8 Cobimetinib (Cotellic)

7.9 Trametinib (Mekinist)

7.10 Tc 99m Tilmanocept (Lymphoseek)

7.11 Dabrafenib (Tafinlar)

7.12 Aldesleukin (Chiron IL-2 & Proleukin)

7.13 Interferon alpha-2b (Intron A, Viraferon & Virtron)

7.14 Interferon-beta-1b - Toray/Daiichi Sankyo (Feron)

7.15 Melanoma Vaccine - AVAX Technologies (MVax)

7.16 Interferon alpha - Swedish Orphan Biovitrim (Multiferon)

7.17 Interferon alpha-2b - Beijing Kawin Technology

7.18 Virulizin (Virulizin)

7.19 Vemurafenib Companion Diagnostic - Roche/Plexxikon (cobas 4800 BRAF V600 Mutation Test)

7.20 Dabrafenib-Trametinib Companion Diagnostic - bioMerieux/ GlaxoSmithKline/ Response Genetics (THxID-BRAF)

7.21 Interferon alpha-2b Biosimilar - Reliance Life Sciences (ReliFeron)

7.22 Technetium Tc 99m Sulfur Colloid Injection – Pharmalucence

7.23 Interferon alpha-2a (Roferon-A)

7.24 Fotemustine (Muforan, Muphoran, Mustoforan & Mustophoran)

7.25 Melanoma Vaccine – GlaxoSmithKline (Melacine)



8. Competitve Landscape

8.1 AB Science

8.2 Celgene Corporation (Abraxis BioScience)

8.3 Array BioPharma

8.4 AVAX Technologies

8.5 Biogen Idec

8.6 BioVex

8.7 Bristol-Myers Squibb

8.8 Enzon Pharmaceuticals

8.9 Eisai Co

8.10 Exelixis

8.11 GlaxoSmithKline

8.12 Lorus Therapeutics (Aptose Bioscience)

8.13 Medarex

8.14 Merck

8.15 Navidea Biopharmaceuticals

8.16 Novartis

8.17 Ono Pharmaceutical

8.18 Onyx Pharmaceuticals

8.19 Pfizer

8.20 Pharmalucence (Sun Pharmaceutical)

8.21 Plexxikon

8.22 QIAGEN

8.23 Roche

8.24 Reliance Life Sciences

8.25 Servier

8.26 TC BioPharm

8.27 Viragen

Figure 1-1: Causes behind Development of Skin Cancer

Figure 1-2: Different Melanomas on the basis of Histology

Figure 2-1: Mechanism of Dacarbazine

Figure 2-2: Mechanism of Vemurafenib

Figure 2-3: Mechanism of Ipilimumab

Figure 2-4: Mechanism of Nivolumab

Figure 3-1: Global Malignant Melanoma Drug Market (US$ Billion), 2015-2020

Figure 3-2: Global Malignant Melanoma Drug Pipeline by Phase (%), 2016

Figure 3-3: Global Malignant Melanoma Drug Pipeline by Phase (Numbers), 2016

Figure 4-1: Malignant Melanoma Drug Market Favorable Features

Figure 4-2: Malignant Melanoma Drug Market Commercialization Challenges

Figure 8-1: AB Science Clinical Pipeline

Figure 8-2: Malignant Melanoma Clinical Pipeline

Figure 8-3: Aptose Biosciences Pipeline

Figure 8-4: Merck Clinical Pipeline

Figure 8-5: Novartis Clinical Pipeline

Figure 8-6: Plexxikon Clinical Pipeline

Figure 8-7: Roche Clinical Pipeline

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Malignant Melanoma Drug Market & Clinical Pipeline Insight Report here

News-ID: 1040877 • Views: 200

More Releases from Kuick Resarch

Global Cell Therapy Market To Surpass US$ 35 Billion By 2026
Global cell therapy market is expected to surpass US$ 35 Billion by 2026 as per recent report “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” published by Kuick Research. Increasing investment, gaining research and development activities along with new technological advancement will drive the global cell therapy market. Download Report: https://www.kuickresearch.com/report-global-cell-therapy-market,-clinical-trials,-therapy-price-and-opportunity-insight-2026.php “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” Report Highlights: • Global Cell Therapy
Cell Therapy Market Size Growth Cell Therapy Clinical Trials Market Forecast 202 …
Cell therapies are still in the infancy stages of the clinical development and are expected to evolve in the market with a vast number of opportunities in the healthcare industry. In order to form a stable base for process evaluation and development it will be essential to understand the quality of cell based products. With an increasing number of cell therapies and clinical indications being assessed, it is clear that
Global Cell Therapy Market Size Analysis Clinical Trials Growth Forecast 2026
"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights: • Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 • Cell Therapy Clinical Trial Insight by Indication, Company & Country • Global Cell Therapy Clinical Pipeline: 767 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Maximum Number of Marketed Cell Therapies In USA: 15 Therapies • Price & Product Insight By Region/Country • Regional Analysis of the Cell Therapy Market Download
CAR T Cell Therapy Changing The Cancer Oncology Drug Market Landscape
" Global CAR T Cell Therapy Market & Clinical Trials Insight 2024" Report Highlights: • CAR T-Cell Therapies Delivery Pipeline & Mechanism of Action • Sales Analysis of CAR - T Cell Therapy • CAR - T Cell Therapy Market Opportunity: US$ 700 Million • CAR-T Cell Therapies Clinical Pipeline by Company, Indication & Phase: 236 Therapies • CAR-T Cell Therapies in Highest Phase: Preclinical • Marketed CAR-T Cell Therapies: 2 ( Yescarta & Kymriah) • Global Market Scenario of

All 5 Releases


More Releases for Melanoma

Global Melanoma Drugs Market Insights, Forecast
Melanoma is the type of cancer, in which the normal melanin-producing cells called melanocytes are turned into cancerous cells. Melanoma is usually, but not always cancer of the skin and is the most dangerous type of cancer. Mutation in melanin-producing melanocytes leads to uncontrolled division of cells forming the malignant tumor. Mainly there are three general categories of melanoma as Cutaneous, mucosal and ocular. Cutaneous melanoma is melanoma of the
Global Drugs for Melanoma Market Insights, Forecast
Melanoma is the type of cancer, in which the normal melanin-producing cells called melanocytes are turned into cancerous cells. Melanoma is usually, but not always cancer of the skin and is the most dangerous type of cancer. Mutation in melanin-producing melanocytes leads to uncontrolled division of cells forming the malignant tumor. Mainly there are three general categories of melanoma as Cutaneous, mucosal and ocular. Cutaneous melanoma is melanoma of the
Intraocular Melanoma Treatment Market Drivers
Neurological disorder diagnostics tools are medical devices, which are used in diagnosis of various neurological disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and Multiple Sclerosis. The devices which are majorly used in diagnosis are imaging tools such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and in-vitro diagnostics tools such as biomarker and biopsy. Increasing prevalence of neurological disorders in the recent past has increased demand for diagnostic
12-06-2017 | Health & Medicine
Fact.MR
Melanoma Cancer Diagnostics Market: 7 Key Takeaways
According to a latest market research by fast-growing market research and consulting firm, the global melanoma cancer diagnostics market is poised to grow at over 7% CAGR and surpass US$ 853.5 million in revenues by 2022. Fact.MR’s report forecasts that North America and Europe will remain the most lucrative markets for melanoma cancer diagnostics market globally. Key takeaways from Fact.MR’s report are, Request Free Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=57 • The U.S. melanoma cancer
Melanoma Treatment Market – Global Industry Insights, 2025
Melanoma is a type of skin cancer that develops from the pigment cells known as melanocytes. It is caused due to high exposure to ultraviolet rays, which leads to sunburn, especially at high altitudes. Melanoma is categorized into three: cutaneous, mucosal, and ocular. Cutaneous affects the skin, mucosal affects the mucous membrane in the mouth and nasal passage, and ocular affects the eye. However, early detection of melanoma helps in
Malignant Melanoma Drug Market Malignant Melanoma Clinical Pipeline Report
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Malignant Melanoma 2. Malignant Melanoma Drug Mechanism of Action 3. Global Malignant Melanoma Market Analysis 3.1 Current Market Scenario 3.2 Global Malignant Melanoma Pipeline Overview 4. Global Malignant Melanoma Drug Market Dynamics 4.1 Favorable Market Parameters 4.2 Commercialization Challenges 5. Global Malignant Melanoma Drug Market Future Prospects 6. Global Malignant Melanoma Clinical Pipeline By